Minute Insight: Abbott Touts 14-Day FreeStyle Libre 3 Data
Executive Summary
Shortly after the FDA approved Abbott's FreeStyle Libre 3 continuous glucose monitor system, the company announced new clinical data showing that it is the most accurate 14-day CGM system available.
You may also be interested in...
ADA 2022 Wrap Up: Iterative Progress On Glucose Control, No Big Surprises
The major players in the diabetes tech sector announced new and re-hashed old clinical data at this year’s American Diabetes Association Scientific Sessions in New Orleans.
Minute Insight: Abbott Is Planning To Combine Glucose And Ketone Measurement Into One Wearable
The company announced that it is developing a new biowearable device that will continuously monitor both glucose and ketone levels with one sensor.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.